defibrotide

Defibrotide is a pharmaceutical compound that has been used in the treatment of certain medical conditions. It is a single-stranded DNA derivative that has anticoagulant and antithrombotic properties. It is believed to work by activating protein C and inhibiting plasminogen activator inhibitor-1 (PAI-1), which helps to prevent blood clots.

The primary indication for defibrotide is the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in patients undergoing hematopoietic stem cell transplantation (HSCT). VOD/SOS is a serious complication that can occur after HSCT, characterized by the blockage of small veins in the liver. Defibrotide has been shown to improve survival rates in patients with severe VOD/SOS.

Defibrotide is administered intravenously. The dosage and duration of treatment depend on the severity of the condition and the patient's response. Like all medications, defibrotide can have side effects. Common side effects may include low blood pressure, nausea, vomiting, and diarrhea. More serious side effects are also possible and should be discussed with a healthcare professional.

The development and approval of defibrotide represent a significant advancement in the management of VOD/SOS, offering a therapeutic option for a condition with historically high mortality. Its mechanism of action targets key pathways involved in clot formation and resolution, underscoring its role in preventing and treating thrombotic complications.